WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2024)
Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
JNJ
JOHNSON & JOHNSON
$350.27B$81.80B$49.47B$38.48B$15.265.60%0.05%215.29%22.73%2024-07-17
LLY
ELI LILLY & CO
$834.88B$35.93B$9.13B$6.14B$6.8229.76%10.69%8.08%1.57%2024-08-08
NVS
NOVARTIS AG
$215.71B$49.92BN/A$15.25B$7.418.81%1.48%125.91%6.77%2024-06-20
SNY
SANOFI
$116.99B$49.94B$14.09B$5.81B$2.326.87%4.70%-32.73%3.84%2024-07-25
AZN
ASTRAZENECA PLC
$246.75B$47.61B$14.25B$6.33B$2.058.60%16.27%34.98%16.57%2024-07-25
GSK
GSK PLC
$82.19B$37.95B$7.29B$5.54B$2.7312.47%-1.11%-67.61%1.40%2024-07-31
BIIB
BIOGEN INC
$33.73B$9.66B$1.85B$1.17B$8.05-4.37%-6.89%-62.80%-19.14%2024-06-20
ABBV
ABBVIE INC
$297.71B$54.40B$17.85B$5.99B$3.37-4.12%10.75%-20.89%-1.20%2024-07-25
GILD
GILEAD SCIENCES INC
$81.06B$27.45B$4.81B$484.00M$0.401.51%4.22%-91.03%-38.59%2024-08-08
AMGN
AMGEN INC
$160.19B$29.53B$12.07B$3.76B$7.0412.76%4.45%-52.46%-11.00%2024-08-01
MRK
MERCK & CO INC
$327.95B$61.40B$8.97B$2.31B$0.916.11%7.35%-82.26%-22.24%2024-07-30
BMY
BRISTOL MYERS SQUIBB CO
$83.52B$45.53B$4.00B-$6.15B-$3.09-0.68%14.35%N/AN/A2024-07-26
GRFS
GRIFOLS SA
$4.81B$7.09B$1.23B$63.78M$0.1013.54%7.27%-69.70%-36.90%
PFE
PFIZER INC
$156.00B$55.09B$4.69B-$309.00M-$0.05-40.86%6.07%N/AN/A2024-07-30
OGN
ORGANON & CO
$5.25B$6.35B$1.44B$1.05B$4.103.29%N/A39.93%N/A2024-08-06
SCLX
SCILEX HOLDING CO
$291.72M$47.05M-$101.67M-$107.96M-$1.3112.54%N/AN/AN/A
AMRN
AMARIN CORP PLC
$319.66M$277.46M-$46.02M-$52.61M-$0.13-23.04%1.42%N/AN/A2024-07-31
MIRA
MIRA PHARMACEUTICALS INC
$10.91M$0.00-$8.95M-$12.36M-$0.67N/AN/AN/AN/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jun 2024?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Johnson & Johnson (NYSE:JNJ)


Johnson & Johnson (NYSE:JNJ) is the top general drug manufacturer stock with a Zen Score of 58, which is 21 points higher than the general drug manufacturer industry average of 37. It passed 21 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -9.92% over the past year, underperforming other general drug manufacturer stocks by -33 percentage points.

Johnson & Johnson has an average 1 year price target of $178.67, an upside of 22.76% from Johnson & Johnson's current stock price of $145.54.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Johnson & Johnson, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)


Eli Lilly & Co (NYSE:LLY) is the second best general drug manufacturer stock with a Zen Score of 55, which is 18 points higher than the general drug manufacturer industry average of 37. It passed 22 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 96.21% over the past year, overperforming other general drug manufacturer stocks by 73 percentage points.

Eli Lilly & Co has an average 1 year price target of $852.06, a downside of -3% from Eli Lilly & Co's current stock price of $878.45.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Eli Lilly & Co, 75% have issued a Strong Buy rating, 12.5% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Novartis Ag (NYSE:NVS)


Novartis Ag (NYSE:NVS) is the third best general drug manufacturer stock with a Zen Score of 51, which is 14 points higher than the general drug manufacturer industry average of 37. It passed 19 out of 38 due diligence checks and has strong fundamentals. Novartis Ag has seen its stock return 6.06% over the past year, underperforming other general drug manufacturer stocks by -17 percentage points.

Novartis Ag has an average 1 year price target of $115.00, an upside of 8.78% from Novartis Ag's current stock price of $105.72.

Novartis Ag stock has a consensus Hold recommendation according to Wall Street analysts. Of the 2 analysts covering Novartis Ag, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 6.03%, which is 3 percentage points higher than the general drug manufacturer industry average of 3.33%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of -3,300% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 5.68%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.33%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of -75.7% indicates that its high dividend yield might not be sustainable for the long-term.

3. Gilead Sciences (NASDAQ:GILD)


Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.67%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.33%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 755% indicates that its high dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.24% in the last day, and up 0.9% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 86, which is 56 points higher than the general drug manufacturer industry average of 30. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -22.77% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -46 percentage points.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 57, which is 27 points higher than the general drug manufacturer industry average of 30. It passed 4 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -8.81% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -32 percentage points.

3. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 57, which is 27 points higher than the general drug manufacturer industry average of 30. It passed 4 out of 7 valuation due diligence checks.

Gsk's stock has gained 17.93% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -6 percentage points.

Are general drug manufacturer stocks a good buy now?

53.33% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 8.07% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 41.03x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.